Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling throughout your body. It is caused by abnormal immune responses. But unlike allergic swelling, HAE is not ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There's a lot of latest developments. You ...

Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly ...

A single dose of the CRISPR-based gene-editing therapy NTLA-2002 significantly reduced angioedema attacks compared with placebo in patients with hereditary angioedema, according to results from a ...

Staying active is an important component of a healthy lifestyle — it improves heart health, builds strength, and supports mental well-being. For people living with hereditary angioedema (HAE), a rare ...

Among patients with hereditary angioedema, baseline attack frequency and disease type did not change improvements in monthly attack rate seen with berotralstat, according to data published in Allergy, ...

Angioedema is a rare but potentially life-threatening adverse reaction to ACE inhibitors. Researchers have now conducted a genome-wide association study (GWAS) with more than 1,000 affected ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A single dose of ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...